Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tegaserod in opioid-induced constipation
NCT00365820Phase 3Terminated
- Sponsor
- Novartis
- Start
- Jul 2006
- Primary completion
- Apr 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in opioid-induced constipation (OIC) comparing Tegaserod with Placebo (2 arms). Primary endpoint: Change from baseline in the number of bowel movements. Started Jul 2006; status: terminated.
02
Drugs
tegaserod
03
Conditions
opioid-induced constipation (OIC)
Beyond the preview
Go deeper on NCT00365820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00365820.